Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 5 minute read Pharma Industry News Can povetacicept reshape autoimmune kidney care? Vertex Pharmaceuticals’ RUBY-3 trial shows promise Vertex’s RUBY-3 trial shows strong 48-week data for povetacicept in IgAN and pMN. Find out how this sets the stage for late-stage trials and regulatory filings. bySrinathNovember 9, 2025